Physicians' Academy for Cardiovascular Education

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD - Houston, TX, USA

Video navigation menu

  • What is bempedoic acid? 01:28
  • Phase III CLEAR program 03:26
  • What is inclisiran? 07:06
  • Phase III ORION pogram 08:48
  • Adherence 11:44

Do you already prescribe inclisiran or bempedoic acid to your patients?

  • Yes
  • No

Educational information

This lecture by Christie Ballantyne was part of an accredited symposium "Redefining intensive LDL-c management in high CV risk patients The case for combination therapy" held during the virtual ESC Congress 2021.

Faculty

Christie Ballantyne MD, cardiologist, and Professor of Medicine at Baylor College of Medicine, Houston, Texas, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by unrestricted educational grants received from Amgen, Sanofi, Novartis and Daiichi Sankyo.

Click here for the meeting report View slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: